EA 1046-Département de Pharmacologie médicale, University Lille Nord de France; Université de Lille 2-Faculté de Médecine; Centre Hospitalier Universitaire; Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France.
1] EA 1046-Département de Pharmacologie médicale, University Lille Nord de France; Université de Lille 2-Faculté de Médecine; Centre Hospitalier Universitaire; Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France [2] EA 4484-Département de Physiologie, University Lille Nord de France; Université de Lille 2-Faculté de Médecine; Centre Hospitalier Universitaire; Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France.
J Cereb Blood Flow Metab. 2014 Mar;34(3):542-51. doi: 10.1038/jcbfm.2013.233. Epub 2014 Jan 8.
In stroke, there is an imperative need to develop disease-modifying drugs able to (1) induce neuroprotection and vasculoprotection, (2) modulate recovery and brain plasticity, and (3) limit the short-term motor and cognitive consequences. We hypothesized that fenofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, could exert a beneficial effect on immediate and short-term poststroke consequences related to its pleiotropic mechanisms. Rats or mice were subjected to focal ischemia to determine the effects of acute treatment by fenofibrate on (i) motor and memory impairment, (2) both cerebral and vascular compartments, (3) inflammation, (4) neurogenesis, and (5) amyloid cascade. We show that fenofibrate administration results in both neuronal and vascular protection and prevents the short-term motor and cognitive poststroke consequences by interaction with several mechanisms. Modulation of PPAR-α generates beneficial effects in the immediate poststroke consequences by mechanisms involving the interactions between polynuclear neutrophils and the vessel wall, and microglial activation. Fenofibrate modulates mechanisms involved in neurorepair and amyloid cascade. Our results suggest that PPAR-α agonists could check the key points of a potential disease-modifying effect in stroke.
在中风中,迫切需要开发能够(1)诱导神经保护和血管保护,(2)调节恢复和大脑可塑性,以及(3)限制短期运动和认知后果的疾病修饰药物。我们假设,非诺贝特,一种过氧化物酶体增殖物激活受体-α(PPAR-α)激动剂,可能通过其多效机制对中风后即刻和短期相关的后果产生有益影响。大鼠或小鼠接受局灶性缺血,以确定非诺贝特的急性治疗对(i)运动和记忆障碍,(2)脑和血管区室,(3)炎症,(4)神经发生和(5)淀粉样蛋白级联的影响。我们表明,非诺贝特的给药导致神经元和血管保护,并通过与几种机制的相互作用来预防中风后的短期运动和认知后果。PPAR-α的调节通过涉及多形核中性粒细胞和血管壁以及小胶质细胞激活之间相互作用的机制产生即刻中风后果的有益效果。非诺贝特调节涉及神经修复和淀粉样蛋白级联的机制。我们的结果表明,PPAR-α激动剂可以检查中风中潜在疾病修饰作用的关键点。